美托洛尔与曲美他嗪治疗老年冠心病心力衰竭的疗效及对患者心功能、心肌重塑和炎症因子的影响分析

Effect of Metoprolol and Trimetazidine on Heart Failure, Heart Function, Myocardial Remodeling and Inflammatory Factors in Elderly Patients with Coronary Heart Disease

目的研究分析美托洛尔与曲美他嗪治疗老年冠心病心力衰竭的疗效及对患者心功能、心肌重塑和炎症因子的影响。方法收集2014年11月至2017年11月我院收治的老年冠心病心力衰竭患者58例作为研究对象,根据随机原则将58例患者均分为对照组和观察组,对照组患者接受常规治疗,观察组患者接受美托洛尔与曲美他嗪治疗,对比两组患者疗效。结果观察组的29例患者临床治疗总有效率明显优于对照组;观察组患者接受治疗后的心功能评分为(93.56±2.45)、心肌重塑评分为(89.56±3.47)、炎症因子评分为(90.41±2.32)明显优于对照组患者接受治疗后的心功能评分(83.24±2.01)、心肌重塑评分为(81.47±2.43)、炎症因子评分为(81.37±21.98)(P<0.05)具有统计学意义。结论美托洛尔与曲美他嗪治疗老年冠心病心力衰竭的疗效显著,并且能够十分有效的改善患者心功能、心肌重塑和炎症因子情况,促进患者康复,值得临床应用。

Objective to study curative effect of metoprolol and trimetazidine in treatment of heart failure patients with elderly coronary heart disease（CHF） and effect on cardiac function, myocardial remodeling and inflammatory factors. Methodscollect 58 cases elderly CHD and heart failure patients treated in our hospital from November 2014 to November 2017 as study objects, according to random principles, divide them into control and observation group. Control group was treated with routine treatment, and observation group with metoprolol and trimetazidine. Compare curative effect of two groups.. Results total effective rate of observation group was significantly higher than control group. Cardiac function scores of observation group were（93.56±2.45）, myocardial remodeling scores were（89.56±3.47）, and inflammatory factor scores were（90.41±2.32）, significantly better than control group after treatment： cardiac function scores（83.24±2.）, myocardial remodeling scores（81.47±2.43） and inflammatory factor scores（81.37±21.98）, with statistical significance,（P〈0.05）. Conclusion metoprolol and trimetazidine has significant effect in treatment of heart failure of elderly patients with coronary heart disease, can improve cardiac function, myocardial remodeling and inflammatory factors effectively, and promote rehabilitation of patients, which is worthy of clinical application.